Impact of sintilimab with first-line therapy on tumor marker response in advanced gastric cancer

doi:10.4251/wjgo.v18.i5.117085

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

(25)

(22)

(0)

(315)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. May 15, 2026; 18(5): 117085
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.117085

Table 3 Comparison of therapeutic efficacy, n (%)

Group	Complete response	Partial response	Stable disease	Progressive disease	Objective response rate	Disease control rate
Control (n = 30)	0 (0.00)	4 (13.33)	10 (33.33)	16 (53.33)	4 (13.33)	14 (46.67)
Combination (n = 30)	0 (0.00)	12 (40.00)	13 (43.33)	9 (30.00)	12 (40.00)	25 (83.33)
χ² value	-				5.455	8.865
P value	-				0.020	0.003

Full Size Table

Citation: Quan HL, Xia L, Hu Y, Wang GY, Wang C. Impact of sintilimab with first-line therapy on tumor marker response in advanced gastric cancer. World J Gastrointest Oncol 2026; 18(5): 117085
URL: https://www.wjgnet.com/1948-5204/full/v18/i5/117085.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i5.117085

Quan HL, Xia L, Hu Y, Wang GY, Wang C. Impact of sintilimab with first-line therapy on tumor marker response in advanced gastric cancer. World J Gastrointest Oncol 2026; 18(5): 117085 [DOI: 10.4251/wjgo.v18.i5.117085]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.